Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 853520 |
Synonyms | |
Therapy Description |
BI 853520 is an inhibitor of PTK2 (FAK), which has demonstrated anti-tumor activity, including tumor growth inhibition and regression (Mol Cancer Ther November 2011 10; A249, PMID: 30756308). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 853520 | IN10018|IN 10018|IN-10018|BI853520|BI-853520 | FAK inhibitor 15 | BI 853520 is an inhibitor of PTK2 (FAK), which has demonstrated anti-tumor activity, including tumor growth inhibition and regression (Mol Cancer Ther November 2011 10; A249, PMID: 30756308). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04109456 | Phase I | BI 853520 + Cobimetinib BI 853520 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | Recruiting | USA | AUS | 0 |